Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more
Aurobindo Pharma Limited (AUROPHARMA) - Net Assets
Latest net assets as of September 2025: ₹350.34 Billion INR
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has net assets worth ₹350.34 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹525.46 Billion) and total liabilities (₹175.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹350.34 Billion |
| % of Total Assets | 66.67% |
| Annual Growth Rate | 19.88% |
| 5-Year Change | 48.88% |
| 10-Year Change | 378.85% |
| Growth Volatility | 14.04 |
Aurobindo Pharma Limited - Net Assets Trend (2004–2025)
This chart illustrates how Aurobindo Pharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aurobindo Pharma Limited (2004–2025)
The table below shows the annual net assets of Aurobindo Pharma Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹326.47 Billion | +9.37% |
| 2024-03-31 | ₹298.51 Billion | +11.17% |
| 2023-03-31 | ₹268.52 Billion | +9.27% |
| 2022-03-31 | ₹245.74 Billion | +12.06% |
| 2021-03-31 | ₹219.29 Billion | +30.34% |
| 2020-03-31 | ₹168.25 Billion | +21.11% |
| 2019-03-31 | ₹138.92 Billion | +18.92% |
| 2018-03-31 | ₹116.82 Billion | +24.62% |
| 2017-03-31 | ₹93.74 Billion | +37.49% |
| 2016-03-31 | ₹68.18 Billion | +31.57% |
| 2015-03-31 | ₹51.82 Billion | +37.23% |
| 2014-03-31 | ₹37.76 Billion | +44.02% |
| 2013-03-31 | ₹26.22 Billion | +11.57% |
| 2012-03-31 | ₹23.50 Billion | -4.05% |
| 2011-03-31 | ₹24.49 Billion | +33.58% |
| 2010-03-31 | ₹18.33 Billion | +47.33% |
| 2009-03-31 | ₹12.44 Billion | +10.39% |
| 2008-03-31 | ₹11.27 Billion | +26.72% |
| 2007-03-31 | ₹8.90 Billion | +8.84% |
| 2006-03-31 | ₹8.17 Billion | +14.39% |
| 2005-03-31 | ₹7.14 Billion | -1.45% |
| 2004-03-31 | ₹7.25 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aurobindo Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 30221650000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹302.22 Billion | 92.55% |
| Common Stock | ₹580.80 Million | 0.18% |
| Other Comprehensive Income | ₹22.98 Billion | 7.04% |
| Other Components | ₹751.10 Million | 0.23% |
| Total Equity | ₹326.53 Billion | 100.00% |
Aurobindo Pharma Limited Competitors by Market Cap
The table below lists competitors of Aurobindo Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mobile World Investment Corp
VN:MWG
|
$4.15 Billion |
|
PriceSmart Inc
NASDAQ:PSMT
|
$4.15 Billion |
|
Hua Hong Semiconductor Limited
PINK:HHUSF
|
$4.15 Billion |
|
Broadex Technologies Co Ltd
SHE:300548
|
$4.15 Billion |
|
Ampol Limited
F:CLZ
|
$4.14 Billion |
|
MDU Resources Group Inc
NYSE:MDU
|
$4.14 Billion |
|
Nordnet AB (publ)
LSE:0A6V
|
$4.14 Billion |
|
Western Superconducting Tech Co Ltd
SHG:688122
|
$4.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aurobindo Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 298,428,000,000 to 326,533,200,000, a change of 28,105,200,000 (9.4%).
- Net income of 34,858,800,000 contributed positively to equity growth.
- Dividend payments of 10,400,000 reduced retained earnings.
- Share repurchases of 9,302,400,000 reduced equity.
- Other comprehensive income decreased equity by 2,664,200,000.
- Other factors increased equity by 5,223,400,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹34.86 Billion | +10.68% |
| Dividends Paid | ₹10.40 Million | -0.0% |
| Share Repurchases | ₹9.30 Billion | -2.85% |
| Other Comprehensive Income | ₹-2.66 Billion | -0.82% |
| Other Changes | ₹5.22 Billion | +1.6% |
| Total Change | ₹- | 9.42% |
Book Value vs Market Value Analysis
This analysis compares Aurobindo Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 85.41x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹15.06 | ₹1286.00 | x |
| 2005-03-31 | ₹14.05 | ₹1286.00 | x |
| 2006-03-31 | ₹14.64 | ₹1286.00 | x |
| 2007-03-31 | ₹13.35 | ₹1286.00 | x |
| 2008-03-31 | ₹16.65 | ₹1286.00 | x |
| 2009-03-31 | ₹19.17 | ₹1286.00 | x |
| 2010-03-31 | ₹28.93 | ₹1286.00 | x |
| 2011-03-31 | ₹38.20 | ₹1286.00 | x |
| 2012-03-31 | ₹40.18 | ₹1286.00 | x |
| 2013-03-31 | ₹44.72 | ₹1286.00 | x |
| 2014-03-31 | ₹64.24 | ₹1286.00 | x |
| 2015-03-31 | ₹88.32 | ₹1286.00 | x |
| 2016-03-31 | ₹120.77 | ₹1286.00 | x |
| 2017-03-31 | ₹160.14 | ₹1286.00 | x |
| 2018-03-31 | ₹199.35 | ₹1286.00 | x |
| 2019-03-31 | ₹237.07 | ₹1286.00 | x |
| 2020-03-31 | ₹287.14 | ₹1286.00 | x |
| 2021-03-31 | ₹374.27 | ₹1286.00 | x |
| 2022-03-31 | ₹419.43 | ₹1286.00 | x |
| 2023-03-31 | ₹458.07 | ₹1286.00 | x |
| 2024-03-31 | ₹509.32 | ₹1286.00 | x |
| 2025-03-31 | ₹560.22 | ₹1286.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aurobindo Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.68%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.99%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.52x
- Recent ROE (10.68%) is below the historical average (17.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 15.01% | 7.22% | 0.81x | 2.58x | ₹362.62 Million |
| 2005 | 0.46% | 0.25% | 0.62x | 2.99x | ₹-680.74 Million |
| 2006 | 8.55% | 4.37% | 0.59x | 3.30x | ₹-117.87 Million |
| 2007 | 22.68% | 9.47% | 0.61x | 3.96x | ₹1.12 Billion |
| 2008 | 21.22% | 9.79% | 0.67x | 3.23x | ₹1.26 Billion |
| 2009 | 8.08% | 3.26% | 0.73x | 3.40x | ₹-238.66 Million |
| 2010 | 30.67% | 15.69% | 0.75x | 2.62x | ₹3.78 Billion |
| 2011 | 23.05% | 12.86% | 0.75x | 2.40x | ₹3.19 Billion |
| 2012 | -5.28% | -2.72% | 0.73x | 2.67x | ₹-3.57 Billion |
| 2013 | 11.28% | 5.00% | 0.81x | 2.79x | ₹332.84 Million |
| 2014 | 42.02% | 12.99% | 1.28x | 2.53x | ₹12.01 Billion |
| 2015 | 30.56% | 12.99% | 0.94x | 2.50x | ₹10.60 Billion |
| 2016 | 28.70% | 14.66% | 0.87x | 2.26x | ₹13.19 Billion |
| 2017 | 24.56% | 15.41% | 0.92x | 1.73x | ₹13.64 Billion |
| 2018 | 20.75% | 14.72% | 0.78x | 1.81x | ₹12.55 Billion |
| 2019 | 17.02% | 12.09% | 0.74x | 1.90x | ₹9.76 Billion |
| 2020 | 16.91% | 12.32% | 0.80x | 1.72x | ₹11.63 Billion |
| 2021 | 24.33% | 21.53% | 0.73x | 1.54x | ₹31.42 Billion |
| 2022 | 10.78% | 11.29% | 0.69x | 1.38x | ₹1.91 Billion |
| 2023 | 7.18% | 7.75% | 0.62x | 1.49x | ₹-7.56 Billion |
| 2024 | 10.63% | 10.94% | 0.64x | 1.51x | ₹1.89 Billion |
| 2025 | 10.68% | 10.99% | 0.64x | 1.52x | ₹2.21 Billion |
Industry Comparison
This section compares Aurobindo Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aurobindo Pharma Limited (AUROPHARMA) | ₹350.34 Billion | 15.01% | 0.50x | $4.14 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |